This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThermoGenesis Reports Fourth Quarter And Full Fiscal Year 2013 Results

RANCHO CORDOVA, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the fourth quarter and year-ended fiscal 2013.

"Fiscal 2013 was a transformative year for ThermoGenesis, punctuated by several key accomplishments, including the divestiture of our non-core products, streamlining of our cost infrastructure and improving our market share within our base business," said Matthew T. Plavan, Chief Executive Officer of ThermoGenesis. "We believe these accomplishments position us well for near term stockholder value creation, a key catalyst of which lies in the future completion of the proposed merger with TotipotentRX ("TotiRX"). By combining our best-in-class technologies and solutions for the processing, preparing and preserving of cell-based products with TotiRX's extensive experience in developing clinically validated therapeutic protocols and cell therapy kits for major therapeutic areas, we expect the combined company to be one of the first fully integrated regenerative medicine companies which we believe substantially enhances the value of our business and will create greater value for our shareholders."

Mr. Plavan added, "And as for the fourth quarter, ThermoGenesis realized a number of important milestones, including the successful launch of a bone marrow transplant program in India and commercial distribution of our AXP System in China, one of the world's fastest growing cord blood markets."

Fourth Quarter 2013 and Recent Highlights

In July 2013, ThermoGenesis and TotiRX announced signing of a definitive merger agreement. The combined company is expected to become one of the first fully integrated regenerative medicine company, developing clinically validated, commercially scalable, point-of-care cell therapies for major therapeutic markets, including orthopedic, cardiovascular and neurologic indications. The combined company is expected to be named Cesca Therapeutics ("Clinical Excellence in Stem Cell Applications") and will continue to trade on NASDAQ. The merger is expected to close in the fourth quarter of calendar year 2013 and is subject to customary closing conditions, certain financial conditions and approval by the stockholders of both companies.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.85 -0.82%
FB $117.83 -0.19%
GOOG $699.29 0.52%
TSLA $211.67 -4.90%
YHOO $36.92 2.60%


Chart of I:DJI
DOW 17,624.38 -26.88 -0.15%
S&P 500 2,048.17 -2.95 -0.14%
NASDAQ 4,714.5420 -11.0970 -0.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs